Donna M. Michel

TL;DR: African Americans carrying two APOL1 risk alleles have a greatly increased risk for glomerular disease, andAPOL1-associated FSGS occurs earlier and progresses to ESRD more rapidly, adding to the evidence base required to determine whether genetic testing for APol1 has a use in clinical practice.

TL;DR: Genetic variation at the MYH9 locus substantially explains the increased burden of FSGS and hypertensive ESKD among African Americans.

TL;DR: Results indicate that genetic variation or mutation of NPHS2 may play a role in late-onset sporadic FS GS, and a common haplotype of noncoding SNPs carried by 20% of African-Americans, but not observed in European-Americans was strongly associated with a 50% reduction in risk for sporadic FSGS.

TL;DR: It is concluded that SNPs in WT1 and WIT1 genes are significantly associated with focal segmental glomerulosclerosis, suggesting that variants in these genes may mediate pathogenesis by altering WT1 function.

TL;DR: The approach described in this article should help nephrologists discuss prognosis with their patients in a way that is patient centered and in accordance with clinical practice guideline recommendations.